Literature DB >> 19366800

Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.

Mindy D Szeto1, Gargi Chakraborty, Jennifer Hadley, Russ Rockne, Mark Muzi, Ellsworth C Alvord, Kenneth A Krohn, Alexander M Spence, Kristin R Swanson.   

Abstract

Glioblastoma multiforme (GBM) are aggressive and uniformly fatal primary brain tumors characterized by their diffuse invasion of the normal-appearing parenchyma peripheral to the clinical imaging abnormality. Hypoxia, a hallmark of aggressive tumor behavior often noted in GBMs, has been associated with resistance to therapy, poorer survival, and more malignant tumor phenotypes. Based on the existence of a set of novel imaging techniques and modeling tools, our objective was to assess a hypothesized quantitative link between tumor growth kinetics [assessed via mathematical models and routine magnetic resonance imaging (MRI)] and the hypoxic burden of the tumor [assessed via positron emission tomography (PET) imaging]. Our biomathematical model for glioma kinetics describes the spatial and temporal evolution of a glioma in terms of concentration of malignant tumor cells. This model has already been proven useful as a novel tool to dynamically quantify the net rates of proliferation (rho) and invasion (D) of the glioma cells in individual patients. Estimates of these kinetic rates can be calculated from routinely available pretreatment MRI in vivo. Eleven adults with GBM were imaged preoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enhanced T1- and T2-weighted MRIs to allow the estimation of patient-specific net rates of proliferation (rho) and invasion (D). Hypoxic volumes were quantified from each FMISO-PET scan following standard techniques. To control for tumor size variability, two measures of hypoxic burden were considered: relative hypoxia (RH), defined as the ratio of the hypoxic volume to the T2-defined tumor volume, and the mean intensity on FMISO-PET scaled to the blood activity of the tracer (mean T/B). Pearson correlations between RH and the net rate of cell proliferation (rho) reached significance (P < 0.04). Moreover, highly significant positive correlations were found between biological aggressiveness ratio (rho/D) and both RH (P < 0.00003) and the mean T/B (P < 0.0007).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366800      PMCID: PMC3760276          DOI: 10.1158/0008-5472.CAN-08-3884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Primary and secondary glioblastomas: from concept to clinical diagnosis.

Authors:  P Kleihues; H Ohgaki
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

Review 2.  Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation.

Authors:  G U Dachs; G M Tozer
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

3.  Continuous growth of mean tumor diameter in a subset of grade II gliomas.

Authors:  Emmanuel Mandonnet; Jean-Yves Delattre; Marie-Laure Tanguy; Kristin R Swanson; Antoine F Carpentier; Hugues Duffau; Philippe Cornu; Rémy Van Effenterre; Ellsworth C Alvord; Laurent Capelle
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

4.  A quantitative model for differential motility of gliomas in grey and white matter.

Authors:  K R Swanson; E C Alvord; J D Murray
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

5.  [18F]fluoroestradiol radiation dosimetry in human PET studies.

Authors:  D A Mankoff; L M Peterson; T J Tewson; J M Link; J R Gralow; M M Graham; K A Krohn
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

6.  Therapeutic targets in radiotherapy.

Authors:  J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-02-01       Impact factor: 7.038

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

Review 8.  Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion.

Authors:  Kristin R Swanson; Carly Bridge; J D Murray; Ellsworth C Alvord
Journal:  J Neurol Sci       Date:  2003-12-15       Impact factor: 3.181

9.  [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Authors:  J G Rajendran; D C Wilson; E U Conrad; L M Peterson; J D Bruckner; J S Rasey; L K Chin; P D Hofstrand; J R Grierson; J F Eary; K A Krohn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-11       Impact factor: 9.236

10.  Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy.

Authors:  K R Swanson; E C Alvord; J D Murray
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more
  65 in total

1.  ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.

Authors:  Kenji Hirata; Shunsuke Terasaka; Tohru Shiga; Naoya Hattori; Keiichi Magota; Hiroyuki Kobayashi; Shigeru Yamaguchi; Kiyohiro Houkin; Shinya Tanaka; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.

Authors:  Nobuyuki Kawai; Yukito Maeda; Nobuyuki Kudomi; Keisuke Miyake; Masaki Okada; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

3.  Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.

Authors:  Olivia J Kelada; Sara Rockwell; Ming-Qiang Zheng; Yiyun Huang; Yanfeng Liu; Carmen J Booth; Roy H Decker; Uwe Oelfke; Richard E Carson; David J Carlson
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

4.  Glial progenitor cell recruitment drives aggressive glioma growth: mathematical and experimental modelling.

Authors:  Susan Christine Massey; Marcela C Assanah; Kim A Lopez; Peter Canoll; Kristin R Swanson
Journal:  J R Soc Interface       Date:  2012-02-07       Impact factor: 4.118

Review 5.  Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.

Authors:  Maria Protopapa; Anna Zygogianni; Georgios S Stamatakos; Christos Antypas; Christina Armpilia; Nikolaos K Uzunoglu; Vassilis Kouloulias
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

6.  To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer.

Authors:  Li Li; Yuchun Wei; Yong Huang; Qingxi Yu; Wenju Liu; Shuqiang Zhao; Jinsong Zheng; Hong Lu; Jinming Yu; Shuanghu Yuan
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 7.  Current progress in patient-specific modeling.

Authors:  Maxwell Lewis Neal; Roy Kerckhoffs
Journal:  Brief Bioinform       Date:  2009-12-02       Impact factor: 11.622

Review 8.  Dissecting cancer through mathematics: from the cell to the animal model.

Authors:  Helen M Byrne
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

9.  Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.

Authors:  Takuya Toyonaga; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Osamu Manabe; Shiro Watanabe; Shunsuke Terasaka; Hiroyuki Kobayashi; Naoya Hattori; Tohru Shiga; Yuji Kuge; Shinya Tanaka; Yoichi M Ito; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-18       Impact factor: 9.236

Review 10.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.